NIH VideoCast - NIH Consensus Development Conference: Inhaled Nitric Oxide Therapy For Premature Infants - Day 1

Skip Navigation

NIH Consensus Development Conference: Inhaled Nitric Oxide Therapy For Premature Infants - Day 1

Loading... Loading video...

Air date:	Wednesday, October 27, 2010, 8:30:00 AM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 185 * This only includes stats from October 2011 and forward.
Category:	Conferences
Runtime:	06:26:19
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	Babies born before the 28th week of pregnancy—more than 30,000 per year in the United States—are particularly vulnerable to breathing problems due to their underdeveloped lungs. Nitric oxide is sometimes used to treat infants with severe breathing problems, and inhaled nitric oxide therapy was approved by the U.S. FDA in 2000 to treat term and near-term infants (born after the 33rd week of pregnancy) with respiratory failure. Since its approval, researchers have examined expanding the use of inhaled nitric oxide therapy to treat premature babies born at less than 34 weeks’ gestation. The National Institutes of Health is convening a Consensus Development Conference October 27-29, 2010 to assess the available scientific evidence related to the benefits and risks of inhaled nitric oxide therapy for premature infants.

NLM Title:	NIH Consensus Development Conference : inhaled nitric oxide therapy for premature infants / NICHD and OMAR.
Author:	National Institute of Child Health and Human Development (U.S.)
Publisher:
Abstract:	(CIT): Babies born before the 28th week of pregnancy--more than 30,000 per year in the United States--are particularly vulnerable to breathing problems due to their underdeveloped lungs. Nitric oxide is sometimes used to treat infants with severe breathing problems, and inhaled nitric oxide therapy was approved by the U.S. FDA in 2000 to treat term and near-term infants (born after the 33rd week of pregnancy) with respiratory failure. Since its approval, researchers have examined expanding the use of inhaled nitric oxide therapy to treat premature babies born at less than 34 weeks" gestation. The National Institutes of Health is convening a Consensus Development Conference October 27-29, 2010 to assess the available scientific evidence related to the benefits and risks of inhaled nitric oxide therapy for premature infants.
Subjects:	Infant, Newborn Infant, Premature, Diseases--therapy Nitric Oxide--therapeutic use Respiratory Tract Diseases--therapy
Publication Types:	Congress Consensus Development Conference, NIH Webcast
NLM Classification:	WS 280
NLM ID:	101549229
CIT Live ID:	9498
Permanent link:	https://videocast.nih.gov/watch=9498

Related Videos...